Výsledky vyhledávání - "Allen Portner"

Akademický článek

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

Autor: Felicia Scaggs Huang, David I. Bernstein, Karen S. Slobod, Allen Portner, Toru Takimoto, Charles J. Russell, Michael Meagher, Bart G. Jones, Robert E. Sealy, Christopher Coleclough, Kristen Branum, Michelle Dickey, Kristen Buschle, Monica McNeal, Mat Makowski, Aya Nakamura, Julia L. Hurwitz

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 17, Iss 2, Pp 554-559 (2021)

SeVRSV is a replication-competent Sendai virus (SeV)-based vaccine carrying the respiratory syncytial virus (RSV) fusion protein (F) gene. Unmanipulated, non-recombinant SeV is a murine parainfluenza virus type 1 (PIV-1) and serves as a Jennerian vac

Externí odkaz: https://doaj.org/article/0024b08a41a0453eab429c20987a46a3

Zobrazit plný text záznamu

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

Autor: Toru Takimoto, Felicia Scaggs Huang, Michelle Dickey, Karen S. Slobod, David I. Bernstein, Allen Portner, Aya Nakamura, Bart G. Jones, Mat Makowski, Charles J. Russell, Christopher Coleclough, Julia L. Hurwitz, Kristen N Buschle, Kristen Branum, Robert E. Sealy, Michael M Meagher, Monica M. McNeal

Publikováno v: Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270458babc11b2440438aab3f5edcd23
https://doi.org/10.1080/21645515.2020.1779517

Zobrazit plný text záznamu

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

Publikováno v: Clinical and Vaccine Immunology. 22:298-303

Human parainfluenza virus type 1 (hPIV-1) is the most common cause of laryngotracheobronchitis (croup), resulting in tens of thousands of hospitalizations each year in the United States alone. No licensed vaccine is yet available. We have developed m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dc68b7e8f7c4e42c7d34a06e683e2fa
https://doi.org/10.1128/cvi.00618-14

Zobrazit plný text záznamu

Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats

Autor: Julia L. Hurwitz, Bart G. Jones, Xiaoyan Zhan, Karen S. Slobod, Robert E. Sealy, Kelli L. Boyd, Toru Takimoto, Charles J. Russell, Allen Portner, Sherri L. Surman

Publikováno v: International Immunology. 27:229-236

The respiratory syncytial virus (RSV) is responsible for as many as 199000 annual deaths worldwide. Currently, there is no standard treatment for RSV disease and no vaccine. Sendai virus (SeV) is an attractive pediatric vaccine candidate because it e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac8ff518ea17713c51c00357d133e625
https://doi.org/10.1093/intimm/dxu107

Zobrazit plný text záznamu

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

Autor: Julia L. Hurwitz, Bart G. Jones, Karen S. Slobod, Philip R. Dormitzer, Charles J. Russell, Robert E. Sealy, Allen Portner, John P. DeVincenzo, Sherri L. Surman

Publikováno v: Vaccine. 32:3264-3273

Respiratory syncytial virus (RSV) is the cause of significant morbidity and mortality among infants, and despite decades of research there remains no licensed vaccine. SeVRSV is a Sendai virus (SeV)-based live intranasal vaccine that expresses the fu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a61717ddd0e3cb65070f390c2a604bf
https://doi.org/10.1016/j.vaccine.2014.03.088

Zobrazit plný text záznamu

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein

Autor: Vasiliy P. Mishin, Allen Portner, Garry L. Taylor, Jonathan A. McCullers, Irina V. Alymova, Pamela Freiden

Publikováno v: Glycobiology. 22:174-180

The hemagglutinin-neuraminidase (HN) glycoprotein is utilized by human parainfluenza viruses for binding to the host cell. By the use of glycan array assays, we demonstrate that, in addition to the first catalytic-binding site, the HN of human parain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b04bd35f8b75446e2932e5144fb941c1
https://doi.org/10.1093/glycob/cwr112

Zobrazit plný text záznamu

N-Linked Glycan at Residue 523 of Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Masks a Second Receptor-Binding Site

Autor: Allen Portner, John P. DeVincenzo, Vasiliy P. Mishin, Irina V. Alymova, Garry L. Taylor, Michael Bose, Makiko Watanabe

Publikováno v: Journal of Virology. 84:3094-3100

The hemagglutinin-neuraminidase (HN) glycoprotein plays a critical role in parainfluenza virus replication. We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906a7eb7d4bc00ad558797cc482c1c73
https://doi.org/10.1128/jvi.02331-09

Zobrazit plný text záznamu

Residues in the Heptad Repeat A Region of the Fusion Protein Modulate the Virulence of Sendai Virus in Mice

Autor: Charles J. Russell, Kelli L. Boyd, John N. Mason, Olga A. Bridges, Laura E. Luque, Allen Portner

Publikováno v: Journal of Virology. 84:810-821

While the molecular basis of fusion (F) protein refolding during membrane fusion has been studied extensively in vitro, little is known about the biological significance of membrane fusion activity in parainfluenza virus replication and pathogenesis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089c96e4d53c800ee86d915acb35f8b2
https://doi.org/10.1128/jvi.01990-09

Zobrazit plný text záznamu

Effect of Hemagglutinin-Neuraminidase Inhibitors BCX 2798 and BCX 2855 on Growth and Pathogenicity of Sendai/Human Parainfluenza Type 3 Chimera Virus in Mice

Autor: Xiaowei Yan, Allen Portner, Y. Sudhakara Babu, Charles J. Russell, Xiaoping Xiong, Makiko Watanabe, Garry L. Taylor, Kelli L. Boyd, Irina V. Alymova, Vasiliy P. Mishin, Scott A. Brown

Publikováno v: Antimicrobial Agents and Chemotherapy. 53:3942-3951

Human parainfluenza virus type 3 (hPIV-3) is a major respiratory tract pathogen that affects young children, but no vaccines or antiviral drugs against it have yet been developed. We developed a mouse model to evaluate the efficacies of the novel par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4946ec55a8fa4aeedfc60324cb63f559
https://doi.org/10.1128/aac.00220-09

Zobrazit plný text záznamu

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV

Autor: Xiaoyan Zhan, Allen Portner, Vasiliy P. Mishin, Bart G. Jones, Charles J. Russell, Julia L. Hurwitz, Sherri L. Surman, Karen S. Slobod

Publikováno v: Vaccine. 27:1848-1857

The human parainfluenza viruses (hPIVs) and respiratory syncytial viruses (RSVs) are the leading causes of hospitalizations due to respiratory viral disease in infants and young children, but no vaccines are yet available. Here we describe the use of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690ef55a2a5877c87b5b420bc4fdee10
https://doi.org/10.1016/j.vaccine.2009.01.041

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání